查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103027

全球中樞神經系統（CNS）治療人工智慧（AI）市場－策略分析與預測（2026-2035）

Global AI in CNS Drug Discovery Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 157 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球中樞神經系統 (CNS) 治療人工智慧 (AI) 市場預計在預測期內將以 15.8% 的複合年成長率成長，從 2026 年的 311,050,000 美元成長到 2035 年的 1,168,940,000 美元。

將人工智慧 (AI) 應用於中樞神經系統 (CNS) 治療藥物的研發，正在改變藥物研究領域中最複雜、最具挑戰性的領域之一。包括阿茲海默症、帕金森氏症、亨廷頓氏症、多發性思覺失調症、憂鬱症、憂鬱症以及其他神經退化性疾病疾病和精神疾病在內的中樞神經系統疾病，由於其複雜的生物學特性、對潛在機制缺乏了解以及歷來較高的藥物研發失敗率，仍然是臨床和商業性面臨的重大挑戰。

傳統的中樞神經系統（CNS）藥物研發過程通常耗時耗力，需要大量資金投入和長期的臨床評估。如今，人工智慧（AI）技術正被擴大應用於目標識別、生物標記發現、化合物篩檢、患者分層、預測建模和臨床試驗最佳化等方面。透過利用機器學習、深度學習、自然語言處理和進階資料分析技術，製藥公司能夠更有效率地分析大量資料集，並更精準地識別出有前景的候選藥物。隨著對創新神經系統疾病治療的需求持續成長，人工智慧有望成為未來中樞神經系統藥物研發的重要驅動力。

市場促進因素

中樞神經系統疾病盛行率上升

推動這一市場發展的主要因素之一是全球神經系統和精神疾病負擔日益加重。人口老化、預期壽命延長以及人們對心理健康意識的提高，都導致了這些疾病在全球範圍內的盛行率不斷上升。

阿茲海默症、帕金森氏症、憂鬱症、思覺失調症、癲癇和其他中樞神經系統疾病的日益普遍，使得創新療法的需求變得迫切。人工智慧驅動的藥物發現平台有望加速新療法的發現，並顯著滿足尚未滿足的醫療需求。

提高藥物發現效率的必要性

與許多其他治療領域相比，中樞神經系統（CNS）藥物研發的成功率歷來較低。大腦的生物學複雜性、預測模型的限制以及跨越血腦障壁的挑戰等因素，都是導致研發成本高昂的原因。

人工智慧技術可以幫助研究人員分析複雜的生物資料集，識別隱藏的關係，並改善候選化合物的選擇，從而有可能縮短開發週期並提高成功率。

擴大人工智慧在製藥業的應用

為了提高生產力和創新能力，製藥和生物技術公司正擴大將人工智慧解決方案融入其研發流程中。人工智慧平台可以輔助標靶發現、分子設計、毒性預測、藥物重定位和臨床試驗最佳化。

隨著人工智慧驅動的調查方法被廣泛接受，對中樞神經系統 (CNS) 療法藥物發現平台的投資正在加速成長，從而擴大了市場機會。

提高生物醫學數據的可用性

基因組資料庫、神經影像庫、電子健康記錄、臨床試驗資料集和真實世界資料（REW）平台的激增，為人工智慧主導的研究創造了豐富的基礎。

先進的演算法能夠處理大量的結構化和非結構化數據，產生傳統調查方法難以發現的洞見。這種不斷擴展的數據生態系統正在顯著推動市場成長。

市場限制因素

數據品質和整合方面的挑戰

儘管現有的醫療和研究數據量龐大，但數據品質、標準化程度和可近性卻存在顯著差異。整合來自多個來源的異質資料集仍然是人工智慧驅動的藥物研發專案面臨的重大挑戰。

不完整或偏差的資料集會影響演算法的效能，降低預測準確率。

法規和檢驗的不確定性

人工智慧在藥物研發中的應用仍處於起步階段，監管人工智慧驅動研究的框架仍在不斷改進。如何證明人工智慧研究結果的可靠性、透明度和可重複性仍然是至關重要的考量。

監管方面的不確定性可能會影響人工智慧驅動的藥物發現解決方案的採用率及其商業化策略。

高昂的實施成本

開發和部署先進的人工智慧平台需要對運算基礎設施、專業人員、軟體開發和數據採集進行大量投資。由於預算限制，中小型生物技術公司和研究機構在採用先進的人工智慧技術方面可能會面臨挑戰。

缺乏同時精通人工智慧和神經科學的專家可能會進一步限制部署工作。

目錄

第1章執行摘要

  • 市場概覽
  • 主要發現
  • 市場概述
  • 高階主管洞察
  • 策略建議
  • 未來市場展望

第2章 疾病與流行病學分析

  • 中樞神經系統疾病概述
    • 阿茲海默症
    • 帕金森氏症
    • 重度憂鬱症（MDD）
    • 躁鬱症
    • 思覺失調症
    • 癲癇
    • 多發性硬化症
    • 肌萎縮側索硬化症（ALS）
    • 亨丁頓舞蹈症
    • 泛自閉症障礙（ASD）
  • 全球中樞神經系統疾病負擔
  • 按適應症分類的流行病學
    • 阿茲海默症病率和發病率
    • 帕金森氏症患者群
    • 憂鬱症患者群
    • 思覺失調症患者族群
    • 癲癇患者群體
    • 多發性硬化症患者族群
  • 按年齡層別分類的疾病負擔
  • 性傳染病負擔
  • 中樞神經系統疾病的經濟負擔
  • 中樞神經系統（CNS）藥物研發中尚未滿足的需求
  • 中樞神經系統藥物臨床試驗的失敗率
  • 人工智慧在解決中樞神經系統（CNS）藥物研發難題中的作用。

第3章 市場動態

  • 市場概覽
  • 市場促進因素
    • 中樞神經系統疾病負擔加重
    • 中樞神經系統（CNS）藥物研發中的高輟學率
    • 擴大人工智慧驅動的藥物發現平台的應用
    • 多體學領域的發展和真實世界數據的可用性提高
    • 加大對精準神經科學的投資
  • 市場限制因素
    • 高品質中樞神經系統資料集的可用性低
    • 人工智慧模型監管方面的不確定性
    • 檢驗人工智慧生成目標的挑戰
    • 資料隱私和安全問題
  • 市場機遇
    • 人工智慧驅動的目標識別
    • 生物標記發現平台
    • 現有藥物再利用的例子
    • 分子設計的人工智慧
    • 數位孿生技術在中樞神經系統調查的應用
  • 市場挑戰
    • 中樞神經系統疾病的生物學複雜性
    • 人工智慧演算法的可解釋性
    • 多模態資料來源的整合
  • 波特五力分析
  • PESTLE分析
  • 價值鏈分析
  • 人工智慧驅動的藥物發現生態系統分析

第4章 商業和市場進入

  • 商業環境概述
  • 中樞神經系統藥物開發經濟學
    • 研發費用
    • 利用人工智慧最佳化臨床試驗成本
    • 透過人工智慧整合提高生產力
  • 策略夥伴關係和授權模式
  • 創業投資與私募股權的發展趨勢
  • 製藥業與人工智慧的合作現狀
  • 商業化面臨的挑戰
  • 相關人員分析
    • 製藥公司
    • 生技公司
    • 人工智慧技術提供者
    • 學術研究機構
    • 監管機構

第5章：創新與通路的現狀

  • 創新整體情況
  • 人工智慧技術應用於中樞神經系統（CNS）療法的藥物研發
    • MAC平台
    • 深度學習模型
    • 下一代的AI平台
    • 圖神經網路
    • 自然語言處理的應用
    • 利用知識圖譜的藥物發現平台
  • 中樞神經系統 (CNS) 藥物研發流程（依研發階段分類）
    • 藥物發現計劃
    • 臨床前階段項目
    • I期臨床試驗項目
    • 二期臨床試驗項目
    • III期臨床試驗項目
  • 管道分析：依指示
    • 阿茲海默症
    • 帕金森氏症
    • 重度憂鬱症
    • 思覺失調症
    • 癲癇
    • 多發性硬化症
    • ALS
    • 其他中樞神經系統疾病
  • 管道分析：按作用機制分析
    • 針對BETA-澱粉樣蛋白的療法
    • Tau蛋白調變器
    • 神經發炎調節劑
    • 突觸可塑性的調節因子
    • 神經保護劑
    • 多巴胺能路徑調變器
  • 管道分析：按模式
    • 低分子化合物
    • 生物製劑
    • 基因治療
    • 基於RNA的療法
    • 細胞療法
  • 專利情勢分析
  • 臨床試驗現狀
  • 策略聯盟和授權協議
  • 資金籌措和投資趨勢

第6章 當前治療狀況

  • 目前中樞神經系統（CNS）治療的範式
  • 按適應症批准的治療方法
    • 阿茲海默症的治療方法
    • 帕金森氏症的治療方法
    • 憂鬱症的治療方法
    • 思覺失調症的治療
    • 癲癇的治療
    • 多發性硬化症的治療方法
  • 傳統中樞神經系統（CNS）藥物研發面臨的挑戰
  • 人工智慧驅動的藥物發現工作流程
  • 比較分析：傳統藥物發現與人工智慧驅動藥物發現的比較
  • 精準醫療和中樞神經系統藥物
  • 未來治療開發模式

第7章 市場規模及預測

  • 全球市場概覽
  • 過往市場分析
  • 市場預測
  • 技術預測
  • 按應用預測
  • 最終用戶預測
  • 依藥物作用方式預測
  • 市場吸引力分析

第8章 市場區隔

  • 依技術類型分類
    • 機器學習（ML）
    • 深度學習（DL）
    • 人工智慧世代
    • 自然語言處理
    • 知識圖譜
    • 電腦視覺
  • 適應症
    • 阿茲海默症
    • 帕金森氏症
    • 重度憂鬱症
    • 思覺失調症
    • 癲癇
    • 多發性硬化症
    • ALS
    • 其他中樞神經系統疾病
  • 最終用戶
    • 製藥公司
    • 生技公司
    • 受託研究機構（CRO）
    • 學術研究機構

第9章 區域分析

  • 北美洲
    • 市場規模和成長分析
    • 需求要素
    • 區域法規概述
    • 競爭加劇程度分析
  • 歐洲
    • 市場規模和成長分析
    • 需求促進因素
    • 區域法規概述
    • 競爭加劇程度分析
  • 亞太地區
    • 市場規模和成長分析
    • 需求促進因素
    • 區域法規概述
    • 競爭加劇程度分析
  • 拉丁美洲
    • 市場規模和成長分析
    • 需求促進因素
    • 區域法規概述
    • 競爭加劇程度分析
  • 中東和非洲
    • 市場規模和成長分析
    • 需求促進因素
    • 區域法規概述
    • 競爭加劇程度分析

第10章 主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第11章 法規與政策概述

  • 全球法規概述
  • 美國法律規範（FDA）
    • 關於人工智慧在藥物研發的應用指南
    • 藥物發現及臨床開發相關法規
    • 資料完整性和驗證要求
  • 歐洲法規結構（EMA）
    • 人工智慧法律及其對醫療領域的影響
    • 藥物研發相關法規
    • 資料管治要求
  • 日本的法律規範（PMDA）
    • 關於人工智慧在藥物研發中應用的相關政策
    • 臨床開發的要求
  • 印度的法規結構（CDSCO）
    • 藥物研發相關法規
    • 數位健康和​​人工智慧的政策
  • 中國的法規結構（NMPA）
    • 人工智慧和醫藥創新相關政策
    • 臨床開發的要求
  • 有關資料隱私和人工智慧管治的法規
  • 智慧財產權和專利框架
  • 人工智慧驅動藥物研發的未來監管趨勢

第12章 競爭格局

  • 市佔率分析
  • 競爭基準
  • 戰略定位分析
  • 製藥業與人工智慧的合作
  • 併購
  • 授權協議和共同開發契約
  • 資金籌措和投資分析
  • 競爭環境儀錶板

第13章：公司簡介

  • Recursion Pharmaceuticals
  • Insilico Medicine
  • Exscientia plc
  • BenevolentAI
  • Schrodinger, Inc.
  • Relay Therapeutics
  • Neumora Therapeutics
  • Evotec SE
  • NVIDIA Corporation
  • Alphabet Inc.

第14章：未來展望

  • 人工智慧（AI）在中樞神經系統（CNS）療法藥物研發的應用：未來發展
  • 生成式人工智慧和基礎模型在藥物發現的應用
  • 人工智慧驅動的精準神經科學
  • 數位生物標記和多體學整合
  • 利用人工智慧最佳化臨床試驗
  • 製藥公司與人工智慧公司未來的合作模式
  • 直至2033年的長期成長機會

第15章 分析方法

  • 分析方法概述
  • 初步調查框架
  • 第二次調查的框架
  • 流行病學資料收集分析方法
  • 管道檢驗分析方法
  • 臨床試驗檢驗方法
  • 市場規模分析方法
  • 預測方法
  • 數據檢驗和三角測量
  • 先決條件和限制
簡介目錄
Product Code: KSI-008818

The Global AI in CNS Drug Discovery Market is projected to grow at a CAGR of 15.8% the forecast period, increasing from USD 311.05 million in 2026 to USD 1,168.94 million by 2035.

The application of artificial intelligence (AI) in CNS drug discovery is transforming one of the most complex and challenging areas of pharmaceutical research. Central nervous system disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy, schizophrenia, depression, and other neurodegenerative and psychiatric conditions, continue to pose significant clinical and commercial challenges due to complex disease biology, limited understanding of underlying mechanisms, and historically high drug development failure rates.

Traditional CNS drug discovery processes often require extensive time, significant financial investment, and prolonged clinical evaluation. AI technologies are increasingly being deployed to improve target identification, biomarker discovery, compound screening, patient stratification, predictive modeling, and clinical trial optimization. By leveraging machine learning, deep learning, natural language processing, and advanced data analytics, pharmaceutical companies can analyze vast datasets more efficiently and identify promising therapeutic candidates with greater precision. As the demand for innovative neurological therapies continues to rise, AI is expected to become a critical enabler of future CNS drug development.

Market Drivers

Rising Prevalence of CNS Disorders

One of the primary drivers of the market is the growing global burden of neurological and psychiatric disorders. Aging populations, increasing life expectancy, and rising awareness of mental health conditions are contributing to higher disease prevalence worldwide.

The increasing incidence of Alzheimer's disease, Parkinson's disease, depression, schizophrenia, epilepsy, and other CNS disorders is creating urgent demand for innovative therapeutic solutions. AI-powered drug discovery platforms offer the potential to accelerate the identification of novel treatment candidates and address substantial unmet medical needs.

Need to Improve Drug Discovery Efficiency

CNS drug development has historically experienced lower success rates compared to many other therapeutic areas. The complexity of brain biology, limited predictive models, and challenges associated with crossing the blood-brain barrier have contributed to high research and development costs.

Artificial intelligence technologies help researchers analyze complex biological datasets, identify hidden relationships, and improve candidate selection, potentially reducing development timelines and increasing the probability of success.

Growing Adoption of AI Across the Pharmaceutical Industry

Pharmaceutical and biotechnology companies are increasingly integrating AI solutions into research workflows to enhance productivity and innovation. AI platforms can support target discovery, molecular design, toxicity prediction, drug repurposing, and clinical trial optimization.

The growing acceptance of AI-driven research methodologies is accelerating investment in specialized CNS drug discovery platforms and expanding market opportunities.

Increasing Availability of Biomedical Data

The proliferation of genomic databases, neuroimaging repositories, electronic health records, clinical trial datasets, and real-world evidence platforms is creating a rich foundation for AI-driven research.

Advanced algorithms can process large volumes of structured and unstructured data to generate insights that would be difficult to identify through conventional research methods. This growing data ecosystem is significantly supporting market expansion.

Market Restraints

Data Quality and Integration Challenges

Although large volumes of healthcare and research data are available, significant variability exists in data quality, standardization, and accessibility. Integrating heterogeneous datasets from multiple sources remains a major challenge for AI-based drug discovery programs.

Incomplete or biased datasets may affect algorithm performance and reduce predictive accuracy.

Regulatory and Validation Uncertainty

The use of artificial intelligence in pharmaceutical development is still evolving, and regulatory frameworks governing AI-assisted research continue to develop. Demonstrating the reliability, transparency, and reproducibility of AI-generated insights remains an important consideration.

Regulatory uncertainty may influence adoption rates and affect commercialization strategies for AI-powered drug discovery solutions.

High Implementation Costs

Developing and deploying advanced AI platforms requires significant investments in computational infrastructure, specialized talent, software development, and data acquisition. Smaller biotechnology firms and research organizations may face challenges in adopting sophisticated AI technologies due to budget constraints.

The shortage of professionals with expertise in both artificial intelligence and neuroscience can further limit implementation efforts.

Technology and Segment Insights

The global AI in CNS drug discovery market can be segmented by technology, application, therapeutic area, end user, and geography.

By technology, the market includes machine learning, deep learning, natural language processing, computer vision, predictive analytics, neural networks, and advanced data mining platforms. Machine learning and deep learning technologies account for a significant share due to their ability to identify patterns within complex biological and clinical datasets.

By application, the market includes target identification and validation, biomarker discovery, compound screening, lead optimization, drug repurposing, toxicity prediction, clinical trial design, and patient stratification. Target identification and drug repurposing are emerging as particularly important applications because AI can rapidly evaluate biological pathways and existing drug databases to identify new therapeutic opportunities.

By therapeutic area, the market encompasses neurodegenerative disorders, psychiatric disorders, neurodevelopmental disorders, epilepsy, multiple sclerosis, chronic pain conditions, and other CNS diseases. Neurodegenerative diseases represent a major segment due to increasing prevalence and substantial unmet treatment needs. Psychiatric disorders also represent a significant area of research activity as scientists seek biologically targeted treatment approaches.

By end user, the market includes pharmaceutical companies, biotechnology firms, contract research organizations, academic institutions, research centers, and healthcare organizations. Pharmaceutical and biotechnology companies account for a major share due to their extensive investments in drug discovery and development programs. Academic institutions continue to play an important role in algorithm development, biomarker discovery, and translational neuroscience research.

Technological advancements are continuously expanding the capabilities of AI-driven CNS research. Integration of multi-omics analysis, digital biomarkers, cloud computing, generative AI models, federated learning systems, and advanced simulation platforms is improving research efficiency and accelerating therapeutic discovery. AI-enabled digital twins and predictive disease modeling are also emerging as promising tools for evaluating treatment responses and optimizing clinical development strategies.

Geographically, North America dominates the market due to strong pharmaceutical research infrastructure, substantial artificial intelligence investments, advanced healthcare systems, and a high concentration of biotechnology companies. Europe maintains a significant market presence supported by neuroscience research initiatives and increasing adoption of digital health technologies. Asia-Pacific is expected to witness the fastest growth owing to expanding biotechnology sectors, increasing healthcare investments, growing AI capabilities, and rising neurological disease burden. Latin America and the Middle East & Africa are gradually increasing participation through healthcare modernization and research collaborations.

Competitive and Strategic Outlook

The AI in CNS drug discovery market is characterized by growing collaboration among pharmaceutical companies, biotechnology firms, artificial intelligence developers, cloud computing providers, academic institutions, and research organizations. Strategic partnerships are becoming increasingly important as organizations seek to combine expertise in neuroscience, computational biology, and machine learning.

Companies are investing heavily in proprietary AI platforms, advanced analytics tools, and integrated drug discovery ecosystems. Collaborative agreements focused on target identification, biomarker discovery, and AI-assisted therapeutic development are becoming common across the industry. Mergers, acquisitions, licensing agreements, and joint research initiatives continue to shape the competitive landscape.

Market participants are also emphasizing explainable AI, regulatory compliance, data security, and model validation to improve industry acceptance and support future commercialization efforts. Organizations that successfully demonstrate the ability to accelerate CNS drug discovery while reducing development risks are expected to gain significant competitive advantages.

Conclusion

The global AI in CNS drug discovery market is positioned for substantial growth through 2031, supported by the increasing prevalence of neurological and psychiatric disorders, rising adoption of artificial intelligence technologies, expanding biomedical data availability, and growing demand for more efficient drug development processes. AI is enabling researchers to address longstanding challenges associated with CNS drug discovery by improving target identification, biomarker development, compound optimization, and clinical trial design. While challenges related to data quality, regulatory uncertainty, and implementation costs remain, continued technological innovation and industry collaboration are expected to drive long-term market expansion and accelerate the development of next-generation CNS therapies.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Overview
  • 1.2 Key Findings
  • 1.3 Market Snapshot
  • 1.4 Executive Insights
  • 1.5 Strategic Recommendations
  • 1.6 Future Market Outlook

2. Disease & Epidemiology Analysis

  • 2.1 Overview of Central Nervous System (CNS) Disorders
    • 2.1.1 Alzheimer's Disease
    • 2.1.2 Parkinson's Disease
    • 2.1.3 Major Depressive Disorder (MDD)
    • 2.1.4 Bipolar Disorder
    • 2.1.5 Schizophrenia
    • 2.1.6 Epilepsy
    • 2.1.7 Multiple Sclerosis
    • 2.1.8 Amyotrophic Lateral Sclerosis (ALS)
    • 2.1.9 Huntington's Disease
    • 2.1.10 Autism Spectrum Disorder (ASD)
  • 2.2 Global Burden of CNS Disorders
  • 2.3 Epidemiology by Indication
    • 2.3.1 Alzheimer's Disease Prevalence and Incidence
    • 2.3.2 Parkinson's Disease Patient Population
    • 2.3.3 Depression Patient Population
    • 2.3.4 Schizophrenia Patient Population
    • 2.3.5 Epilepsy Patient Population
    • 2.3.6 Multiple Sclerosis Patient Population
  • 2.4 Disease Burden by Age Group
  • 2.5 Disease Burden by Gender
  • 2.6 Economic Burden of CNS Disorders
  • 2.7 Unmet Needs in CNS Drug Development
  • 2.8 Clinical Trial Failure Rates in CNS Therapeutics
  • 2.9 Role of AI in Addressing CNS Drug Discovery Challenges

3. Market Dynamics

  • 3.1 Market Overview
  • 3.2 Market Drivers
    • 3.2.1 Rising CNS Disease Burden
    • 3.2.2 High Attrition Rates in CNS Drug Development
    • 3.2.3 Increasing Adoption of AI-Based Drug Discovery Platforms
    • 3.2.4 Growth in Multi-Omics and Real-World Data Availability
    • 3.2.5 Rising Investment in Precision Neuroscience
  • 3.3 Market Restraints
    • 3.3.1 Limited Availability of High-Quality CNS Datasets
    • 3.3.2 Regulatory Uncertainty Around AI Models
    • 3.3.3 Validation Challenges for AI-Generated Targets
    • 3.3.4 Data Privacy and Security Concerns
  • 3.4 Market Opportunities
    • 3.4.1 AI-Driven Target Identification
    • 3.4.2 Biomarker Discovery Platforms
    • 3.4.3 Drug Repurposing Applications
    • 3.4.4 Generative AI for Molecule Design
    • 3.4.5 Digital Twin Technologies in CNS Research
  • 3.5 Market Challenges
    • 3.5.1 Biological Complexity of CNS Disorders
    • 3.5.2 Explainability of AI Algorithms
    • 3.5.3 Integration of Multi-Modal Data Sources
  • 3.6 Porter's Five Forces Analysis
  • 3.7 PESTLE Analysis
  • 3.8 Value Chain Analysis
  • 3.9 AI Drug Discovery Ecosystem Analysis

4. Commercial & Market Access

  • 4.1 Commercial Landscape Overview
  • 4.2 CNS Drug Development Economics
    • 4.2.1 Research and Development Costs
    • 4.2.2 Clinical Trial Cost Optimization Through AI
    • 4.2.3 Productivity Gains from AI Integration
  • 4.3 Strategic Partnerships and Licensing Models
  • 4.4 Venture Capital and Private Equity Activity
  • 4.5 Pharmaceutical-AI Collaboration Landscape
  • 4.6 Commercialization Challenges
  • 4.7 Stakeholder Analysis
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 AI Technology Providers
    • 4.7.4 Academic Research Institutes
    • 4.7.5 Regulatory Authorities

5. Innovation & Pipeline Landscape

  • 5.1 Innovation Landscape Overview
  • 5.2 AI Technologies Used in CNS Drug Discovery
    • 5.2.1 Machine Learning Platforms
    • 5.2.2 Deep Learning Models
    • 5.2.3 Generative AI Platforms
    • 5.2.4 Graph Neural Networks
    • 5.2.5 Natural Language Processing Applications
    • 5.2.6 Knowledge Graph-Based Discovery Platforms
  • 5.3 CNS Drug Discovery Pipeline by Development Stage
    • 5.3.1 Discovery Stage Programs
    • 5.3.2 Preclinical Stage Programs
    • 5.3.3 Phase I Clinical Programs
    • 5.3.4 Phase II Clinical Programs
    • 5.3.5 Phase III Clinical Programs
  • 5.4 Pipeline Analysis by Indication
    • 5.4.1 Alzheimer's Disease
    • 5.4.2 Parkinson's Disease
    • 5.4.3 Major Depressive Disorder
    • 5.4.4 Schizophrenia
    • 5.4.5 Epilepsy
    • 5.4.6 Multiple Sclerosis
    • 5.4.7 ALS
    • 5.4.8 Other CNS Disorders
  • 5.5 Pipeline Analysis by Mechanism of Action
    • 5.5.1 Amyloid Beta Targeting Therapies
    • 5.5.2 Tau Protein Modulators
    • 5.5.3 Neuroinflammation Modulators
    • 5.5.4 Synaptic Plasticity Regulators
    • 5.5.5 Neuroprotective Agents
    • 5.5.6 Dopaminergic Pathway Modulators
  • 5.6 Pipeline Analysis by Modality
    • 5.6.1 Small Molecules
    • 5.6.2 Biologics
    • 5.6.3 Gene Therapies
    • 5.6.4 RNA-Based Therapeutics
    • 5.6.5 Cell Therapies
  • 5.7 Patent Landscape Analysis
  • 5.8 Clinical Trial Landscape
  • 5.9 Strategic Collaborations and Licensing Agreements
  • 5.10 Funding and Investment Trends

6. Treatment Landscape

  • 6.1 Current CNS Treatment Paradigm
  • 6.2 Approved Therapies by Indication
    • 6.2.1 Alzheimer's Disease Treatments
    • 6.2.2 Parkinson's Disease Treatments
    • 6.2.3 Depression Treatments
    • 6.2.4 Schizophrenia Treatments
    • 6.2.5 Epilepsy Treatments
    • 6.2.6 Multiple Sclerosis Treatments
  • 6.3 Challenges in Conventional CNS Drug Discovery
  • 6.4 AI-Enabled Drug Discovery Workflow
  • 6.5 Comparative Analysis: Traditional vs AI-Driven Drug Discovery
  • 6.6 Precision Medicine and CNS Therapeutics
  • 6.7 Future Treatment Development Models

7. Market Size & Forecast

  • 7.1 Global Market Overview
  • 7.2 Historical Market Analysis (2021-2025)
  • 7.3 Market Forecast (2026-2033)
  • 7.4 Forecast by Technology Type
  • 7.5 Forecast by Application
  • 7.6 Forecast by End User
  • 7.7 Forecast by Drug Modality
  • 7.8 Market Attractiveness Analysis

8. Market Segmentation

  • 8.1 By Technology Type
    • 8.1.1 Machine Learning
    • 8.1.2 Deep Learning
    • 8.1.3 Generative AI
    • 8.1.4 Natural Language Processing
    • 8.1.5 Knowledge Graphs
    • 8.1.6 Computer Vision
  • 8.2 By Indication
    • 8.2.1 Alzheimer's Disease
    • 8.2.2 Parkinson's Disease
    • 8.2.3 Major Depressive Disorder
    • 8.2.4 Schizophrenia
    • 8.2.5 Epilepsy
    • 8.2.6 Multiple Sclerosis
    • 8.2.7 ALS
    • 8.2.8 Other CNS Disorders
  • 8.3 By End User
    • 8.3.1 Pharmaceutical Companies
    • 8.3.2 Biotechnology Companies
    • 8.3.3 Contract Research Organizations (CROs)
    • 8.3.4 Academic and Research Institutes

9. Geographical Analysis

  • 9.1 North America
    • 9.1.1 Market Size and Growth Analysis
    • 9.1.2 Demand Drivers
    • 9.1.3 Regional Regulatory Overview
    • 9.1.4 Competitive Intensity Analysis
  • 9.2 Europe
    • 9.2.1 Market Size and Growth Analysis
    • 9.2.2 Demand Drivers
    • 9.2.3 Regional Regulatory Overview
    • 9.2.4 Competitive Intensity Analysis
  • 9.3 Asia-Pacific
    • 9.3.1 Market Size and Growth Analysis
    • 9.3.2 Demand Drivers
    • 9.3.3 Regional Regulatory Overview
    • 9.3.4 Competitive Intensity Analysis
  • 9.4 Latin America
    • 9.4.1 Market Size and Growth Analysis
    • 9.4.2 Demand Drivers
    • 9.4.3 Regional Regulatory Overview
    • 9.4.4 Competitive Intensity Analysis
  • 9.5 Middle East & Africa
    • 9.5.1 Market Size and Growth Analysis
    • 9.5.2 Demand Drivers
    • 9.5.3 Regional Regulatory Overview
    • 9.5.4 Competitive Intensity Analysis

10. Key Countries Analysis

  • 10.1 United States
  • 10.2 Canada
  • 10.3 Germany
  • 10.4 United Kingdom
  • 10.5 France
  • 10.6 Italy
  • 10.7 Spain
  • 10.8 China
  • 10.9 Japan
  • 10.10 India
  • 10.11 South Korea
  • 10.12 Australia
  • 10.13 Brazil
  • 10.14 Mexico
  • 10.15 Saudi Arabia
  • 10.16 South Africa

11. Regulatory & Policy Landscape

  • 11.1 Global Regulatory Overview
  • 11.2 United States Regulatory Framework (FDA)
    • 11.2.1 AI in Drug Development Guidance
    • 11.2.2 Drug Discovery and Clinical Development Regulations
    • 11.2.3 Data Integrity and Validation Requirements
  • 11.3 Europe Regulatory Framework (EMA)
    • 11.3.1 AI Act and Healthcare Implications
    • 11.3.2 Drug Development Regulations
    • 11.3.3 Data Governance Requirements
  • 11.4 Japan Regulatory Framework (PMDA)
    • 11.4.1 AI-Enabled Drug Development Policies
    • 11.4.2 Clinical Development Requirements
  • 11.5 India Regulatory Framework (CDSCO)
    • 11.5.1 Drug Development Regulations
    • 11.5.2 Digital Health and AI Policies
  • 11.6 China Regulatory Framework (NMPA)
    • 11.6.1 AI and Pharmaceutical Innovation Policies
    • 11.6.2 Clinical Development Requirements
  • 11.7 Data Privacy and AI Governance Regulations
  • 11.8 Intellectual Property and Patent Frameworks
  • 11.9 Future Regulatory Trends for AI Drug Discovery

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Competitive Benchmarking
  • 12.3 Strategic Positioning Analysis
  • 12.4 Pharmaceutical-AI Partnerships
  • 12.5 Mergers and Acquisitions
  • 12.6 Licensing and Co-Development Agreements
  • 12.7 Funding and Investment Analysis
  • 12.8 Competitive Dashboard

13. Company Profiles

  • 13.1 Recursion Pharmaceuticals
  • 13.2 Insilico Medicine
  • 13.3 Exscientia plc
  • 13.4 BenevolentAI
  • 13.5 Schrodinger, Inc.
  • 13.6 Relay Therapeutics
  • 13.7 Neumora Therapeutics
  • 13.8 Evotec SE
  • 13.9 NVIDIA Corporation
  • 13.10 Alphabet Inc.

14. Future Outlook

  • 14.1 Future Evolution of AI in CNS Drug Discovery
  • 14.2 Generative AI and Foundation Models in Drug Development
  • 14.3 AI-Driven Precision Neuroscience
  • 14.4 Digital Biomarkers and Multi-Omics Integration
  • 14.5 AI-Enabled Clinical Trial Optimization
  • 14.6 Future Partnership Models Between Pharma and AI Companies
  • 14.7 Long-Term Growth Opportunities Through 2033

15. Methodology

  • 15.1 Research Methodology Overview
  • 15.2 Primary Research Framework
  • 15.3 Secondary Research Framework
  • 15.4 Epidemiology Data Collection Methodology
  • 15.5 Pipeline Validation Methodology
  • 15.6 Clinical Trial Verification Approach
  • 15.7 Market Size Estimation Methodology
  • 15.8 Forecasting Approach
  • 15.9 Data Validation and Triangulation
  • 15.10 Assumptions and Limitations